EvilCorporations.com • Case No. 3:24-cv-02129-BTM-MSB • 36 min read

CVS Labeled Its Sleep Pill “Non Habit-Forming.” The Science Said Otherwise. They Sold It Anyway.

Filed November 13, 2024 • United States District Court, Southern District of California • McIntire v. CVS Pharmacy, Inc.

The Non-Financial Ledger: What a Two-Word Lie Costs in the Real World

You can’t sleep. You haven’t slept well in months. You drag yourself to the CVS across the street — the one with the bright fluorescent lights that feel aggressive at 10pm — and you stand in front of a wall of sleep products trying to make a responsible choice. You’re not looking to get hooked on anything. You’re looking for help.

So you read the label. You see “Non habit-forming” printed right there on the front, under the product name, big enough to see without squinting. You are not a pharmacologist. You have no reason to know that the active ingredient causing drowsiness — diphenhydramine — shares a mechanism with drugs that have landed people in rehabilitation clinics. You trust the label because that is what labels are for.

You buy it. You take it that night. It works. You take it the next night. And the night after that. Two weeks in, something feels off. The pill doesn’t hit the way it used to. You need to take two to get the same effect. You tell yourself it’s fine — the label said it wouldn’t become a habit. But your body has already adapted. The receptors in your brain have adjusted around the chemical. You are dependent on it now, in a way your body will protest if you stop abruptly.

That is the story Meghan McIntire is telling in federal court on behalf of herself and potentially millions of other Americans. She bought CVS Acetaminophen PM in San Diego in May 2024. She read the “non habit-forming” label. She relied on it. She developed a habit. And she’s suing.

What this lawsuit captures — but what no lawsuit can fully price — is the erosion of something most people take for granted: the ability to trust what a corporation prints on a box. Sleep deprivation is already its own public health crisis. The CDC links insufficient sleep to depression, ADHD, obesity, type 2 diabetes, cardiovascular disease, cancer, and Alzheimer’s disease. People who reach for an over-the-counter sleep aid are already vulnerable. They’re already struggling. The “non habit-forming” label isn’t just a marketing claim — it’s a promise made to someone in distress, at their most trusting moment, that CVS allegedly had no basis to make.

For elderly users, the stakes compound further. Long-term use of diphenhydramine by adults 65 and older is associated with development of dementia and Alzheimer’s disease due to its anticholinergic properties, according to the complaint. The people most likely to reach for an over-the-counter sleep aid because they can’t afford a sleep study or a prescription — the elderly, the uninsured, the working poor — are the people most likely to bear the worst consequences of this lie.

There is no dollar figure in this complaint yet for what one ruined night of sleep costs when it multiplies into months of dependency. There is no settlement number attached to the psychological weight of discovering that you developed a reliance on something you were explicitly told was safe. What is documented is this: CVS put two words on a box, profited from the trust those words generated, and according to federal court filings, they had every reason to know those words were not true.

Legal Receipts: What CVS Put in Writing — and What It Proves

The complaint in McIntire v. CVS Pharmacy, Inc. is specific, sourced, and damaging. These are direct quotes from the court filing, alongside a breakdown of exactly what each one establishes.

“Defendant falsely and misleadingly labels its Acetaminophen PM Extra Strength Pain Reliever, Nighttime Sleep-Aid Diphenhydramine HCl Product as ‘non habit-forming.’ The ‘non habit-forming’ claim on the Product’s packaging is conspicuous and designed to grab the consumer’s attention. The Product prominently claims ‘non habit-forming’ on the primary display panel of the front label or packaging underneath the Product’s name and a description of its usage.” — Complaint, ¶¶ 22–23, Case 3:24-cv-02129-BTM-MSB

• This establishes that CVS placed the false claim on the most premium, high-visibility real estate on the package — the primary display panel — where manufacturers put their most persuasive selling points. This is not an asterisk. It is the headline.
• The placement is legally significant. The front-panel location shows intent to communicate the claim to consumers at the moment of decision-making, not bury it in fine print.

“Diphenhydramine elicits a cocaine-like pattern of stimulation of dopamine transmission that can lead to misuse of medications containing diphenhydramine.” — Complaint, ¶9, Case 3:24-cv-02129-BTM-MSB

• This is not a fringe claim — it is a pharmacological description of how diphenhydramine interacts with the brain’s reward circuitry. The same mechanism that makes cocaine addictive is being activated by an ingredient CVS labeled “non habit-forming.”
• A product that triggers dopamine stimulation in the brain is, by definition, capable of creating psychological dependency. The “non habit-forming” label is directly contradicted by basic neurochemistry.

“Tolerance can develop in as little as 1–2 weeks, requiring users to take larger and larger doses for the same sedating effect, and causing dependency in users who find they need diphenhydramine to fall asleep. The result is habitual use.” — Complaint, ¶¶7, 34, Case 3:24-cv-02129-BTM-MSB

• This directly maps the product’s active ingredient to the clinical definition of habit formation: escalating dose requirements and dependency. It matches both the APA’s definition of “habit” and Merriam-Webster’s definition cited in the complaint itself.
• A product that causes escalating dose requirements within two weeks of normal use cannot truthfully be called “non habit-forming” under any standard dictionary or clinical definition.

“Defendant knew, or should have known, that the ‘non habit-forming’ claim would lead reasonable consumers into believing that the Product was safe and would not result in habitual use based on internal conjoint and other marketing studies. Defendant labeled and packaged the Product with the ‘non habit-forming’ claim based in part on its market research.” — Complaint, ¶47(b), Case 3:24-cv-02129-BTM-MSB

• This is the most damaging allegation in the complaint. CVS did not stumble into this claim accidentally — the complaint alleges the company conducted internal marketing research to understand what this label would communicate to consumers, then used that knowledge to write a label that exploited exactly that understanding.
• In other words: CVS allegedly knew consumers would believe the “non habit-forming” claim, knew consumers wanted a non-habit-forming product, and chose to use that language to capture those sales while knowing the product did not meet the standard consumers were applying.

“Among drug overdose deaths in 2017 that mentioned at least one specific drug on the death certificate, the ten drugs most frequently involved included fentanyl, heroin, cocaine, methamphetamine, alprazolam, oxycodone, morphine, methadone, hydrocodone, and diphenhydramine.” — Complaint, ¶28, citing CDC data, Case 3:24-cv-02129-BTM-MSB

• The CDC placed diphenhydramine on the same list as fentanyl, heroin, and cocaine in 2017 overdose death data. This is federal public health data — not a plaintiff’s advocacy document.
• Among 92,033 overdose deaths during 2019–2020, 13,574 (14.7%) were antihistamine-positive. Of those, diphenhydramine accounted for 71.1% of antihistamine-positive deaths. This is the ingredient CVS printed “Non habit-forming” next to.

“Defendant deliberately chose to market the Product with the ‘non habit-forming’ claim thereby misleading consumers into buying or overpaying for the Product.” — McIntire v. CVS Pharmacy, Inc., ¶47(d)

“Defendant, as the manufacturer and marketer of the Product, had exclusive control over the ‘non habit-forming’ claim’s inclusion on the Product’s label, packaging, and advertisements — i.e., Defendant readily and easily could have stopped using the ‘non habit-forming’ claim to sell the Product.” — Complaint, ¶47(d), Case 3:24-cv-02129-BTM-MSB

• This forecloses any argument that CVS was constrained by regulation or supply chain partners. The label language was CVS’s own choice, made in-house, and within their power to change at any time. They kept it.
• The complaint uses the phrase “readily and easily” — meaning there was no structural barrier to removing the false claim. CVS chose to leave it there.

Societal Impact Mapping: The Reach of a Two-Word Label

Public Health

The individual harm described by McIntire scales into a population-level crisis when you consider who buys OTC sleep aids and what diphenhydramine actually does at scale.

• The CDC found that among 92,033 overdose deaths in 2019–2020, 13,574 (14.7%) were antihistamine-positive. Of those, 99.6% involved first-generation antihistamines — primarily diphenhydramine, which accounted for 71.1% of antihistamine-positive overdose deaths. This is not a rare edge case. This is a documented cause of mass death.
• Diphenhydramine appeared on the CDC’s list of the ten most frequently cited drugs on death certificates for drug overdose deaths in 2017 — the same list that includes fentanyl, heroin, and cocaine. A product labeled “non habit-forming” shares a federal public health death-count category with the opioid epidemic’s main killers.
• In adults 65 and older, long-term, frequent use of first-generation antihistamines like diphenhydramine is associated with the development of dementia and Alzheimer’s disease. Elderly people — who are disproportionately sleep-deprived and more likely to reach for an affordable OTC solution — are being exposed to dementia risk under the cover of a false safety label.
• Diphenhydramine’s half-life can be as long as 18 hours, producing next-day impairment including poor attention, reduced memory, poor sensory-motor performance, and — in school-aged children — reduced academic performance. In a simulation of 40 drivers, diphenhydramine produced the worst driving performance of any tested substance, worse than alcohol.
• The Global Allergy and Asthma European Network and the Canadian Society of Allergy and Clinical Immunology both recommend restricting first-generation antihistamines like diphenhydramine to behind-the-counter or prescription-only availability, based on precisely the harms documented in this case. The United States has taken no such action.
• Overdose with diphenhydramine presents as sedation leading to coma in adults. In children, it presents as paradoxical stimulation with agitation and confusion, followed by extreme sedation. Cardiac toxicity — including prolonged QTc and arrhythmias — has also been documented. None of this is disclosed by the “non habit-forming” label.

“Users can quickly develop a tolerance, requiring larger and larger doses for the same sedating effect, and finding that they are dependent on it to fall asleep. Tolerance can develop in as little as 1–2 weeks.” — McIntire v. CVS Pharmacy, Inc., ¶34

Economic Inequality

The financial harm in this lawsuit is not just about the price of a bottle of sleep pills. It is about the structural exploitation of people who cannot afford better options and who are systematically denied accurate information to make safe choices.

• The complaint alleges that consumers paid a price premium for the CVS Acetaminophen PM product specifically because of the “non habit-forming” claim. That means every person who bought this product based on that label paid more than they should have for something that did not deliver the safety attribute they were paying for. CVS captured that premium as profit.
• The over-the-counter sleep aid market is a $65 billion global industry, according to the complaint. A significant portion of that revenue is driven by marketing claims like “non habit-forming” — which differentiate products in a crowded market and justify higher prices. False claims in this category function as a tax on sleep-deprived consumers who have no independent way to verify pharmacological accuracy.
• People who rely on OTC sleep aids instead of prescription medications or clinical sleep treatment are, by definition, people who either lack insurance coverage for those options or cannot afford them. The false “non habit-forming” label was designed to appeal most strongly to exactly the consumer who is already financially constrained and looking for a safe, cheap, accessible solution.
• Dependency on diphenhydramine creates downstream financial costs. Users who develop tolerance must buy more product to achieve the same effect. Users who develop dependency face potential withdrawal symptoms if they stop — symptoms that may drive clinical care costs. The false label that created the dependency also created the financial trap.
• The class encompasses buyers across California, Florida, Michigan, Minnesota, Missouri, New Jersey, Massachusetts, Washington, Illinois, and New York — a national footprint of consumers who paid a premium under false pretenses. The aggregate damages threshold in the complaint is $5,000,000, but that figure reflects only the legal floor for federal jurisdiction, not the full scope of consumer financial harm.

The “Cost of a Life” Metric

The over-the-counter sleep aid market generates nearly $65 billion per year globally. The false “non habit-forming” label is what keeps CVS’s product on the premium shelf instead of the generic one.

What Now: Who to Watch, Who to Contact, and How to Fight Back

The lawsuit is filed. The case is active. But the “non habit-forming” label may still be on store shelves while this litigation proceeds. Here is what you can do and who deserves pressure.

CVS Corporate Leadership

• The complaint names CVS Pharmacy, Inc. as the sole defendant. CVS is headquartered in Woonsocket, Rhode Island. The defendant is identified as the manufacturer, marketer, distributor, and advertiser of the Acetaminophen PM product.
• Corporate Officer: [REDACTED – Not in Source]. The complaint does not name individual CVS executives or board members. Accountability for the labeling decision rests with the Product Marketing leadership and the regulatory compliance team at CVS corporate.
• CVS’s registered agent received a certified demand letter on July 2, 2024. CVS chose not to comply. That decision to continue selling the product with the false label after receiving formal legal notice is documented in the court record.

Regulatory Watchlist

• FDA (Food and Drug Administration): The FDA regulates OTC drug labeling under 21 CFR. A “non habit-forming” claim on an OTC drug product containing a documented dependency-risk ingredient is a potential false labeling violation under the Federal Food, Drug, and Cosmetic Act. File a MedWatch report at fda.gov/safety/medwatch.
• FTC (Federal Trade Commission): The FTC enforces truth-in-advertising standards. False and deceptive advertising claims on consumer product packaging fall within FTC jurisdiction under Section 5 of the FTC Act. File a complaint at reportfraud.ftc.gov.
• State Attorneys General: The complaint invokes California’s UCL, FAL, and CLRA — plus consumer protection laws in Michigan, Minnesota, New Jersey, Missouri, Florida, Massachusetts, Washington, Illinois, and New York. Contact your state AG’s consumer protection division directly.
• CFPB (Consumer Financial Protection Bureau): Where price premiums charged under false pretenses are at issue in consumer financial harm, the CFPB has broad investigative authority. File at consumerfinance.gov/complaint.

Mutual Aid and Organizing

• If you bought CVS Acetaminophen PM: Document your purchase. Keep receipts, photos of the packaging, and any records of when you used the product. This documentation is material to the class action. Visit ClassAction.org — the complaint is searchable in their database — to track case developments and determine if you may be a class member.
• If you or someone you know developed dependency: Contact Bursor & Fisher, P.A. (ltfisher@bursor.com or bscott@bursor.com) or Smith Krivoshey, PC (yeremey@skclassactions.com or joel@skclassactions.com), attorneys of record for the plaintiff class. Your experience is relevant and valued by this litigation.
• Organize locally: Pharmacy boards and city councils can demand local CVS stores pull misleadingly labeled products pending litigation outcomes. Local pharmacist associations can be contacted to raise professional standards pressure within the industry.
• Spread the information: The OTC sleep aid industry counts on consumers not knowing the pharmacology of what they are buying. Sharing this reporting with anyone who buys OTC sleep aids — especially elderly family members — is direct harm reduction. The science on diphenhydramine dependency has existed in peer-reviewed literature since at least 1986. The information asymmetry is deliberate and profitable.